Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 85,700 shares, an increase of 724.0% from the February 13th total of 10,400 shares. Based on an average trading volume of 2,040,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 5.5% of the company’s stock are sold short.

Salarius Pharmaceuticals Stock Up 3.8 %

Shares of NASDAQ:SLRX opened at $0.98 on Thursday. The company has a market capitalization of $1.55 million, a price-to-earnings ratio of -0.12 and a beta of 0.59. The company has a 50 day moving average of $1.83 and a two-hundred day moving average of $1.64. Salarius Pharmaceuticals has a 52-week low of $0.90 and a 52-week high of $7.20.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.